Hey #ASCO2023, keep following !

Let's have a 👀 at the LUNAR phase 3 trial,
showing an OS benefit with tumor treating fields (TTFs) in addition to SoC in platinum refractory meta NSCLC❗️

3.3 months median OS improvement,
Wow... a new SoC ❓

A few thoughts🧵👇
1/7 First the design :
OPEN LABEL 👇

+again and again, a restricted physician's choice
(see our work here : bit.ly/3DsYqPx)

but let's be fair, it's the same in both arms
2/7

Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023

- setting = residual or recurrent disease
- primary EP = PFS = improved from 11.1 to 27.7 Mo (16.6)

Here are some toughts 🧵
1/6 First, we can see that median time from diagnosis ≥ 2.5 years in both groups, so it really looks like mostly recurrent disease.

Now let's make some comparison with another trial, the "PCV trial" -->
This trial was in first-line patients ❗️
2/6